VA
CTMX icon

VR Adviser’s CytomX Therapeutics CTMX Stock Holding History

VR Adviser’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7M Sell
4,982,124
-5,000,000
-50% -$19.1M 0.57% 25
2026
Q1 		$46.9M Sell
9,982,124
-5,579,376
-36% -$28.3M 1.75% 16
2025
Q4 		$66.3M Hold
15,561,500
– – 3.27% 10
2025
Q3 		$49.6M Buy
15,561,500
+1,591,618
+11% +$3.58M 2.79% 11
2025
Q2 		$31.7M Buy
+13,969,882
New +$22.5M 2.38% 13

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

VR Adviser's CTMX Position: Q2 2026 in Review

VR Adviser reduced its CytomX Therapeutics (CTMX) stake by 50% in Q2 2026, selling an estimated $19.1M and leaving 4,982,124 shares worth $18.7M. The position accounts for 0.57% of the portfolio, ranked #25.

VR Adviser first reported a position in CTMX in Q2 2025 and has held it in 5 quarters since. The position peaked at $66.3M in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • VR Adviser held 4,982,124 shares of CytomX Therapeutics worth $18.7M as of Q2 2026.
  • VR Adviser sold 5,000,000 CytomX Therapeutics shares in Q2 2026, an estimated $19.1M.
  • CytomX Therapeutics made up 0.57% of VR Adviser's portfolio in Q2 2026, its #25 holding.
  • VR Adviser first reported a position in CytomX Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • VR Adviser's CytomX Therapeutics position peaked at $66.3M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.